Schrödinger

Schrödinger (NASDAQ: SDGR) is the world's leading computational chemistry and physics-based molecular simulation company, transforming drug discovery and materials research since 1990. Founded by Professor Richard Friesner at Columbia University, Schrödinger's platform suite — including Maestro, Glide, Jaguar, Prime, and FEP+ — enables scientists to model molecular interactions at quantum mechanical precision, predicting how drug candidates bind to disease targets and behave in the body before any physical synthesis.

In July 2026, Schrödinger launched Bunsen, its AI co-scientist embedded in the discovery platform — combining physics-based rigor with AI-driven hypothesis generation and experiment design. Bristol-Myers Squibb immediately signed a strategic agreement to deploy Bunsen, joining a customer base that includes 500+ global pharma and materials companies (BMS, Sanofi, Takeda, Pfizer, Eli Lilly). With $255.87M in 2025 revenue (23% growth), 27% ACV growth in Q2 2026, a raised drug discovery revenue guidance of $65-75M for FY26, and the company turning net income positive, Schrödinger is one of the most financially mature computational drug discovery platforms in the public markets.

Schrödinger is the platform of choice for pharmaceutical scientists, computational chemists, and biotech R&D teams requiring the highest accuracy in molecular simulation — particularly for challenging lead optimization, binding affinity prediction, and ADMET profiling where physics-based models deliver superior results.

Schrödinger offers software through subscription licenses and hosted cloud access.

Enterprise pharma customers access the full suite (Maestro, Glide, FEP+, Jaguar, Prime, and Bunsen AI) through annual software licensing agreements. Pricing is tiered by organization size, usage volume, and modules required. Enterprise software ACV reached $198.5M in 2025.

Academic and government institutions access Schrödinger tools through educational licensing at significantly reduced rates. Cloud-hosted subscriptions are also available for teams preferring managed infrastructure.

Drug discovery partnerships with pharma (BMS, Sanofi, Takeda) are structured as sponsored research and co-development agreements with milestone-based payments. Contact Schrödinger through schrodinger.com for enterprise pricing, academic licenses, or partnership inquiries.